News summaryCaris Life Sciences Investor RelationsNov 4, 2026, 12:00 PM
Caris Life Sciences reports Q3 growth and raises 2026 revenue guidance
On November 4, 2026, Caris reported Q3 revenue of $275.4 million, up 27% year over year, and raised 2026 revenue guidance. It reported 61,500 clinical cases, launched Caris Assure therapy-response monitoring, and said Caris Confirm MRD assay was targeted to launch before year-end.